氮芥凝胶局部治疗蕈样肉芽肿型皮肤T细胞淋巴瘤的临床潜力：当前疗效和安全性数据综述
Clinical potential of mechlorethamine gel for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma: a review on current efficacy and safety data.
作者信息
Liner Kendall, Brown Celeste, McGirt Laura Y
机构信息
Division of Dermatology, Medical College of Georgia at Augusta Health, Augusta, GA, USA.
School of Medicine, University of North Carolina at Chapel Hill, Carolinas Medical Center, Charlotte, NC, USA.
出版信息
Drug Des Devel Ther. 2018 Jan 31;12:241-254. doi: 10.2147/DDDT.S137106. eCollection 2018.
Abstract
Nitrogen mustard is a chemotherapeutic agent that has a well-documented safety and efficacy profile in the treatment of cutaneous T-cell lymphoma. Development of nitrogen mustard formulations and treatment regimens has been studied extensively over the last 40 years. In the last 5 years, a new gel formulation has been developed that is associated with a decrease in delayed hypersensitivity reactions. The authors in this review found that while the gel formulation may result in a decrease of allergic contact dermatitis, this advantage has been replaced by a higher number of irritant contact reactions and a decrease in complete response rate. The gel formulation has a complete response rate of 13.8%, which is a decrease in efficacy when compared to aqueous-based preparations of similar concentrations.
摘要
氮芥是一种化疗药物，在治疗皮肤T细胞淋巴瘤方面有着充分记录的安全性和有效性。在过去40年里，对氮芥制剂和治疗方案的研发进行了广泛研究。在过去5年中，开发出了一种新的凝胶制剂，其与迟发型超敏反应的减少有关。该综述的作者发现，虽然凝胶制剂可能会导致过敏性接触性皮炎减少，但这一优势已被更多的刺激性接触反应和完全缓解率的降低所取代。凝胶制剂的完全缓解率为13.8%，与类似浓度的水性制剂相比，其疗效有所降低。
相似文献
1
Clinical potential of mechlorethamine gel for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma: a review on current efficacy and safety data.
Drug Des Devel Ther. 2018 Jan 31;12:241-254. doi: 10.2147/DDDT.S137106. eCollection 2018.
2
Mechlorethamine gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma.
Expert Rev Clin Pharmacol. 2014 Sep;7(5):591-7. doi: 10.1586/17512433.2014.944500. Epub 2014 Jul 28.
3
Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides.
JAMA Dermatol. 2013 Jan;149(1):25-32. doi: 10.1001/2013.jamadermatol.541.
4
Real-world experience with mechlorethamine gel in patients with mycosis fungoides-cutaneous lymphoma: Preliminary findings from a prospective observational study.
J Am Acad Dermatol. 2020 Sep;83(3):928-930. doi: 10.1016/j.jaad.2019.12.070. Epub 2020 Feb 20.
5
A prospective study of cutaneous intolerance to topical mechlorethamine therapy in patients with cutaneous T-cell lymphomas. French Study Group of Cutaneous Lymphomas.
Arch Dermatol. 1999 Nov;135(11):1349-53. doi: 10.1001/archderm.135.11.1349.
6
In brief: mechlorethamine gel (Valchlor) for cutaneous T-Cell lymphoma.
Med Lett Drugs Ther. 2015 Apr 27;57(1467):e66.
7
The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma.
Am J Clin Dermatol. 2021 May;22(3):407-414. doi: 10.1007/s40257-021-00591-x. Epub 2021 Mar 3.
8
Management of Mycosis Fungoides with Topical Chlormethine/Mechlorethamine Gel: A Columbia University Cutaneous Lymphoma Center Experience.
Acta Derm Venereol. 2021 Sep 8;101(9):adv00544. doi: 10.2340/00015555-3911.
9
Nitrogen mustard gel-induced inflammation triggers lymphomatoid papulosis in patients with mycosis fungoides.
J Dermatol. 2020 May;47(5):546-550. doi: 10.1111/1346-8138.15276. Epub 2020 Feb 26.
10
Optimizing Care and Compliance for the Treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma With Mechlorethamine Gel.
Clin J Oncol Nurs. 2015 Dec;19(6):E131-9. doi: 10.1188/15.CJON.E131-E139.
引用本文的文献
1
The Novel Achievements in Oncological Metabolic Radio-Therapy: Isotope Technologies, Targeted Theranostics, Translational Oncology Research.
Med Sci (Basel). 2025 Aug 1;13(3):107. doi: 10.3390/medsci13030107.
2
A practical and safer model of nitrogen mustard injury in cornea.
PLoS One. 2025 Jul 3;20(7):e0327622. doi: 10.1371/journal.pone.0327622. eCollection 2025.
3
Nitrogen mustard induces dynamic nuclear protein spectrum change and DNA-protein crosslinking, with p97 mediating repair.
Heliyon. 2024 Sep 4;10(17):e37401. doi: 10.1016/j.heliyon.2024.e37401. eCollection 2024 Sep 15.
4
Immunosequencing applications in cutaneous T-cell lymphoma.
Front Immunol. 2023 Dec 21;14:1300061. doi: 10.3389/fimmu.2023.1300061. eCollection 2023.
5
Multidisciplinary Approach to the Diagnosis and Therapy of Mycosis Fungoides.
Healthcare (Basel). 2023 Feb 18;11(4):614. doi: 10.3390/healthcare11040614.
6
Harnessing the immune system in the treatment of cutaneous T cell lymphomas.
Front Oncol. 2023 Jan 12;12:1071171. doi: 10.3389/fonc.2022.1071171. eCollection 2022.
7
Gene Regulations upon Hydrogel-Mediated Drug Delivery Systems in Skin Cancers-An Overview.
Gels. 2022 Sep 2;8(9):560. doi: 10.3390/gels8090560.
8
How we treat mycosis fungoides and Sézary syndrome.
Clin Adv Hematol Oncol. 2021 Sep;19(9):573-581.
9
Post hoc Analysis of a Randomized, Controlled, Phase 2 Study to Assess Response Rates with Chlormethine/Mechlorethamine Gel in Patients with Stage IA-IIA Mycosis Fungoides.
Dermatology. 2022;238(2):347-357. doi: 10.1159/000516138. Epub 2021 Jun 4.
10
C6 Ceramide (d18:1/6:0) as a Novel Treatment of Cutaneous T Cell Lymphoma.
Cancers (Basel). 2021 Jan 13;13(2):270. doi: 10.3390/cancers13020270.
本文引用的文献
1
Mechlorethamine gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma.
Expert Rev Clin Pharmacol. 2014 Sep;7(5):591-7. doi: 10.1586/17512433.2014.944500. Epub 2014 Jul 28.
2
Secondary cancers, comorbidities and mortality associated with nitrogen mustard therapy in patients with mycosis fungoides: a 30-year population-based cohort study.
Br J Dermatol. 2014 Mar;170(3):699-704. doi: 10.1111/bjd.12620.
3
Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides.
JAMA Dermatol. 2013 Jan;149(1):25-32. doi: 10.1001/2013.jamadermatol.541.
4
Topical nitrogen mustard therapy in patients with mycosis fungoides or parapsoriasis.
J Eur Acad Dermatol Venereol. 2013 Feb;27(2):163-8. doi: 10.1111/j.1468-3083.2011.04433.x. Epub 2012 Jan 9.
5
Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC).
Blood. 2007 Sep 15;110(6):1713-22. doi: 10.1182/blood-2007-03-055749. Epub 2007 May 31.
6
Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective study.
Arch Dermatol. 2005 Sep;141(9):1117-20. doi: 10.1001/archderm.141.9.1117.
7
Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience.
Arch Dermatol. 2003 Feb;139(2):165-73. doi: 10.1001/archderm.139.2.165.
8
Treatment of cutaneous T cell lymphoma: current status and future directions.
Am J Clin Dermatol. 2002;3(3):193-215. doi: 10.2165/00128071-200203030-00006.
9
Ointment-based mechlorethamine treatment for mycosis fungoides.
Cancer. 1983 Dec 15;52(12):2214-9. doi: 10.1002/1097-0142(19831215)52:12<2214::aid-cncr2820521207>3.0.co;2-h.
10
Response of mycosis fungoides to topical chemotherapy with mechlorethamine.
Arch Dermatol. 1984 Dec;120(12):1585-90.
Zotero 插件